{"id":33961,"date":"2020-08-28T17:50:17","date_gmt":"2020-08-28T16:50:17","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33961"},"modified":"2023-05-09T21:50:37","modified_gmt":"2023-05-09T20:50:37","slug":"davide-zocco","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/","title":{"rendered":"Davide Zocco"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Davide Zocco<\/h2>\n<h4>Head of R&amp;D at Exosomics<\/h4>\n\t<p>Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&amp;D pipeline the development of molecular assays for detection of EV shuttled mutations.<\/p>\n<p>In 2015 he took on the role of the Head of Molecular Diagnostics. Today he is responsible for development of EV-DNA and EV-RNA targeted solutions and for management of clinical testing of assay prototypes.<\/p>\n<p>Davide actively participates in scouting for new technologies, as well as internal IP strategy and pre-market launch of RUO and diagnostic kits. Prior to joining Exosomics he gained academic training and experience in molecular biology and signaling mechanisms of chronic inflammatory disease and cancer. He holds a PhD from University College Dublin (Ireland) and he was a postdoctoral research fellow at Harvard Medical School (USA).<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1.jpg\" alt=\"davide_zocco_exosomics_Photo_1\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"davide_zocco_exosomics_Photo_1\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Extracellular vesicles (EVs)\n\t<\/h3>\n<ul>\n<li>Use of EVs for liquid biopsy approaches: advantages and current challenges<\/li>\n<li>Standardization of blood collection and processing for the clinical use of EVs<\/li>\n<li>Searching for tumor-derived EVs with SoRTEVTM and SeleCTEVTM enrichment technologies<\/li>\n<li>A proof-of-concept study for the early detection of multiple cancers with an EV-based assay<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.exosomics.it\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.exosomics.it\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/davide-zocco-4278714\/\" target=\"_blank\" rel=\"noopener\">Visit profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Davide Zocco Head of R&amp;D at Exosomics Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&amp;D pipeline the development of molecular assays for detection of EV shuttled mutations. In 2015 he took on the role of the Head of Molecular Diagnostics. Today he is responsible for development of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33962,"parent":33918,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33961","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Davide Zocco &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&amp;D pipeline the development of molecular assays for detection of EV shuttled mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Davide Zocco &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&amp;D pipeline the development of molecular assays for detection of EV shuttled mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-09T20:50:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/\",\"name\":\"Davide Zocco &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg\",\"datePublished\":\"2020-08-28T16:50:17+00:00\",\"dateModified\":\"2023-05-09T20:50:37+00:00\",\"description\":\"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the development of molecular assays for detection of EV shuttled mutations.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liquid Biopsy 2020 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Davide Zocco\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Davide Zocco &#8226; BioTech Pharma Summit","description":"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the development of molecular assays for detection of EV shuttled mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/","og_locale":"en_US","og_type":"article","og_title":"Davide Zocco &#8226; BioTech Pharma Summit","og_description":"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the development of molecular assays for detection of EV shuttled mutations.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-05-09T20:50:37+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/","name":"Davide Zocco &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg","datePublished":"2020-08-28T16:50:17+00:00","dateModified":"2023-05-09T20:50:37+00:00","description":"Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the development of molecular assays for detection of EV shuttled mutations.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Liquid Biopsy 2020 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/"},{"@type":"ListItem","position":3,"name":"Davide Zocco"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33961"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33961\/revisions"}],"predecessor-version":[{"id":38339,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33961\/revisions\/38339"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33962"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}